WO2019203753A3 - The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent - Google Patents
The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent Download PDFInfo
- Publication number
- WO2019203753A3 WO2019203753A3 PCT/TR2018/050806 TR2018050806W WO2019203753A3 WO 2019203753 A3 WO2019203753 A3 WO 2019203753A3 TR 2018050806 W TR2018050806 W TR 2018050806W WO 2019203753 A3 WO2019203753 A3 WO 2019203753A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dapoxetine
- inhibitor
- pharmaceutical combination
- emetic agent
- phosphodiesterase type
- Prior art date
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 239000002111 antiemetic agent Substances 0.000 title abstract 2
- 229940125683 antiemetic agent Drugs 0.000 title abstract 2
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 title abstract 2
- 229960005217 dapoxetine Drugs 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a pharmaceutical combination comprising dapoxetine, a PDE5 inhibitor and furthermore at least one anti-emetic agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18915505.4A EP3723743A4 (en) | 2017-12-15 | 2018-12-13 | The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201720443 | 2017-12-15 | ||
| TR2017/20443 | 2017-12-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2019203753A2 WO2019203753A2 (en) | 2019-10-24 |
| WO2019203753A3 true WO2019203753A3 (en) | 2020-01-16 |
Family
ID=68240624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2018/050806 WO2019203753A2 (en) | 2017-12-15 | 2018-12-13 | The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3723743A4 (en) |
| WO (1) | WO2019203753A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US20150202168A1 (en) * | 2012-08-17 | 2015-07-23 | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
-
2018
- 2018-12-13 WO PCT/TR2018/050806 patent/WO2019203753A2/en unknown
- 2018-12-13 EP EP18915505.4A patent/EP3723743A4/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US20150202168A1 (en) * | 2012-08-17 | 2015-07-23 | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3723743A4 (en) | 2021-09-08 |
| EP3723743A2 (en) | 2020-10-21 |
| WO2019203753A2 (en) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USD873911S1 (en) | Type font | |
| USD883728S1 (en) | Kettle | |
| USD992849S1 (en) | Microfiber booklet | |
| USD796010S1 (en) | Connection for piping | |
| USD938613S1 (en) | Shop interior | |
| USD879874S1 (en) | Typeface | |
| USD877806S1 (en) | Typefaces | |
| USD846153S1 (en) | Truss | |
| EP3782998A4 (en) | Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof | |
| USD760837S1 (en) | Teaching aid | |
| WO2019203753A3 (en) | The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent | |
| EP3965772A4 (en) | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof | |
| USD847266S1 (en) | Adinkra card game | |
| SG11201908281VA (en) | Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof | |
| WO2019086646A8 (en) | Feline leukemia virus vaccine | |
| WO2019203752A3 (en) | Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent | |
| WO2019074826A3 (en) | Bi-layer pharmaceutical tablet formulation | |
| EP3911324A4 (en) | 1,8-naphthyridinone compounds and uses thereof | |
| WO2017188720A3 (en) | Quinazoline derivative or its salt and pharmaceutical composition comprising the same | |
| USD848524S1 (en) | Type font | |
| USD849138S1 (en) | Writing instrument | |
| WO2019074464A3 (en) | The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 | |
| USD834956S1 (en) | Watch | |
| WO2019173382A8 (en) | Gracilin a and congeners as immunosuppressive and neuroprotective agents | |
| WO2019203755A3 (en) | A solid oral dosage form comprising linagliptin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2018915505 Country of ref document: EP Effective date: 20200715 |